Chronoscale Holdings Corp quarterly report, Q1 FY2018

Business context and reporting period

Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) filed this unaudited Form 10-Q for the quarter ended March 31, 2018. The filing describes a company that develops and sells exoskeletons for medical rehabilitation and industrial use, alongside engineering services. The request metadata names Chronoscale Holdings Corp., but the filing itself identifies Ekso Bionics Holdings, Inc.

Financial performance and position

Unless noted otherwise, amounts are in U.S. dollars; financial statement figures below are in millions.

MetricQ1 2018Q1 2017 / prior year-end
Revenue$2.518$1.436; up 75% year over year
Gross profit and margin$0.767; 30.5%$0.352; 24.5%
Operating loss$(8.613)$(8.141)
Net loss$(7.901); $(0.13) per share$(8.302); $(0.38) per share
Operating cash used$(6.745)$(7.254)
Cash$20.572$27.813 at Dec. 31, 2017
Debt, net of discounts and costs$6.623Current $2.333; long-term $4.290
Working capital$17.909Current assets $27.937; current liabilities $10.028
  • Medical device revenue was $2.122 million, including $1.663 million of device sales and $0.387 million of service, support and rentals. Industrial revenue was $0.396 million. Engineering services had no revenue in the quarter, versus $0.028 million a year earlier.
  • Operating expenses were $9.380 million, up 10%. Sales and marketing rose 26% to $3.853 million; R&D fell 37% to $1.808 million; and general and administrative rose 47% to $3.738 million.
  • Q1 net loss included a $0.732 million gain from revaluing warrant liabilities. The warrant liability fell to $0.916 million from $1.648 million at year-end; this non-cash gain helped reduce reported net loss despite a higher operating loss.
  • Cash declined $7.241 million during the quarter. Investing used $0.031 million and financing used $0.399 million, primarily for term-loan principal payments.

Material changes versus the prior comparable period

  • Revenue rose $1.082 million, primarily from higher medical device sales; management reported a $1.2 million increase in medical revenue, partly offset by a $0.1 million decline in industrial revenue.
  • Gross profit increased $0.415 million, and gross margin improved to about 30.5% from 24.5%, principally due to medical device sales.
  • Operating loss widened by $0.472 million as total operating expenses increased. Higher sales and marketing and G&A costs more than offset lower R&D spending.
  • Net loss narrowed by $0.401 million, substantially reflecting the favorable swing in warrant revaluation, rather than improved operating results. Weighted-average shares increased to 60.146 million from 21.899 million, affecting per-share comparisons.
  • Cash used in operations improved by $0.509 million year over year, which management attributed primarily to lower employment costs following a 2017 workforce reduction.

Outlook, risks and unusual items

  • Liquidity and going concern: Management states cash is not forecast to fund operations for the 12 months after issuance, raising substantial doubt about the company’s ability to continue as a going concern. It estimates resources will meet obligations into Q1 2019 under assumptions including modest revenue growth and potential increased medical rentals, but says significant additional financing is required. There is no assurance financing will be available on acceptable terms; equity financing could dilute shareholders, and failure to secure funds could require expense reductions or curtailed operations.
  • A debt covenant required at least $5.526 million of unrestricted cash at the latest measurement; the company reported compliance and estimated effective unrestricted cash of $15.046 million. The required amount is recalculated monthly. The term loan bears interest at 30-day U.S. LIBOR plus 5.41%, matures January 2021, and is secured by substantially all assets other than intellectual property itself.
  • Management plans continued investment in rehabilitation clinical and sales initiatives, a potential home-use exoskeleton, and industrial products. It highlighted alternative sales and rental channels for EksoVest, EksoZeroG and Ekso GT. No quantified revenue, earnings or cash-flow guidance is provided.
  • Risks include lengthy and variable sales cycles, customer adoption and reimbursement, clinical-trial outcomes, regulatory requirements, competition, foreign-exchange exposure, and the need for financing. A shareholder derivative suit filed in March 2018 alleges fiduciary-duty and related claims concerning internal controls; management says the suit is without merit and plans to defend it. Management separately concluded disclosure controls were effective and reported no material quarterly change in internal control over financial reporting.
  • Management turnover is a stated risk. Subsequent to quarter-end, the CFO announced retirement; the filing describes a transition, severance and possible consulting arrangements. A shareholder vote scheduled for June 7, 2018 was to seek ratification of prior amendments to authorized common shares and the equity plan.
  • The company adopted ASC 606 on January 1, 2018 using the modified retrospective method; adoption had no cumulative balance-sheet adjustment and no material effect on revenue amounts or timing.

Important facts for investors to verify

  • Availability, timing, cost and terms of additional financing, and the company’s cash runway relative to the disclosed going-concern uncertainty.
  • Monthly compliance with the debt liquidity covenant, debt amortization and the effect of financing terms on assets and future cash needs.
  • Whether medical device revenue growth, rentals and improved gross margin are sustainable, particularly given the quarter’s higher operating loss.
  • Progress and outcomes of clinical trials, regulatory status, and customer adoption across medical and industrial markets.
  • Developments in the derivative and securities litigation, management transition, and the shareholder ratification votes relating to authorized shares and the equity plan.
Disclaimer:
This AI-generated summary by MetaQuotes is based on SEC filings and may contain errors. Verify important details against the original SEC filings.